Sorafenib suppresses the cell cycle and induces the apoptosis of hepatocellular carcinoma cell lines in serum-free media
- Authors:
- Minoru Tomizawa
- Fuminobu Shinozaki
- Takao Sugiyama
- Shigenori Yamamoto
- Makoto Sueishi
- Takanobu Yoshida
View Affiliations
Affiliations: Department of Gastroenterology, National Hospital Organization Shimoshizu Hospital, Chiba 284-0003, Japan, Department of Radiology, National Hospital Organization Shimoshizu Hospital, Chiba 284-0003, Japan, Department of Rheumatology, National Hospital Organization Shimoshizu Hospital, Chiba 284-0003, Japan, Department of Pediatrics, National Hospital Organization Shimoshizu Hospital, Chiba 284-0003, Japan, Department of Internal Medicine, National Hospital Organization Shimoshizu Hospital, Yotsukaido, Chiba 284-0003, Japan
- Published online on: July 21, 2010 https://doi.org/10.3892/etm.2010.131
-
Pages:
863-866
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
To suppress the invasion of hepatocellular carcinoma (HCC) cells into surrounding connective tissues during metastasis, we investigated the usefulness of sorafenib. In order to search for model cell lines, cell numbers were counted to reveal cell lines with the potential to proliferate in serum-free media. Cell proliferation and cell motility were analyzed with the MTS and wound assay, respectively. 5-Bromo-2'-deoxyuridine (BrdU) labeling and mitotic and apoptotic indices were analyzed to assess the cell cycle and apoptosis. The expression levels of cyclin D1 and the cleavage of caspase-3 were analyzed by Western blotting. HLF cells exhibited growth in the serum-free medium, while the other cell lines examined did not. Sorafenib suppressed the cell proliferation and motility of the HLF cells in the serum-free media. Both indices of BrdU and mitotic potential decreased and the apoptotic index was increased in the serum-free media with sorafenib, suggesting that the cell cycle was suppressed and apoptosis was induced. The expression levels of cyclin D1 decreased and the cleavage of caspase-3 was noted in the serum-free media with sorafenib. Sorafenib may be suitable for molecular therapy to suppress the metastasis of HCC.
View References
1.
|
Kondo Y, Kondo F, Wada K and Okabayashi A:
Pathologic features of small hepatocellular carcinoma. Acta Pathol
Jpn. 36:1149–1161. 1986.PubMed/NCBI
|
2.
|
Tomizawa M, Kondo F and Kondo Y: Growth
patterns and interstitial invasion of small hepatocellular
carcinoma. Pathol Int. 45:352–358. 1995. View Article : Google Scholar : PubMed/NCBI
|
3.
|
Gupta GP and Massague J: Cancer
metastasis: building a framework. Cell. 127:679–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
4.
|
Takasu M, Tada Y, Wang JO, Tagawa M and
Takenaga K: Resistance to apoptosis induced by microenvironmental
stresses is correlated with metastatic potential in Lewis lung
carcinoma. Clin Exp Metastasis. 17:409–416. 1999. View Article : Google Scholar : PubMed/NCBI
|
5.
|
Boraldi F, Annovi G, Paolinelli-Devincenzi
C, Tiozzo R and Quaglino D: The effect of serum withdrawal on the
protein profile of quiescent human dermal fibroblasts in primary
cell culture. Proteomics. 8:66–82. 2007. View Article : Google Scholar : PubMed/NCBI
|
6.
|
Wilhelm SM, Carter C, Tang L, et al: BAY
43-9006 exhibits broad spectrum oral antitumor activity and targets
the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in
tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004.
View Article : Google Scholar : PubMed/NCBI
|
7.
|
Liu L, Cao Y, Chen C, et al: Sorafenib
blocks the RAF/MEK/ ERK pathway, inhibits tumor angiogenesis, and
induces tumor cell apoptosis in hepatocellular carcinoma model
PLC/PRF/5. Cancer Res. 66:11851–11858. 2006. View Article : Google Scholar : PubMed/NCBI
|
8.
|
Furuse J, Ishii H, Nakachi K, Suzuki E,
Shimizu S and Nakajima K: Phase I study of sorafenib in Japanese
patients with hepatocellular carcinoma. Cancer Sci. 99:159–165.
2008.PubMed/NCBI
|
9.
|
Pennisi PA, Barr V, Nunez NP, Stannard B
and Le Roith D: Reduced expression of insulin-like growth factor I
receptors in MCF-7 breast cancer cells leads to a more metastatic
phenotype. Cancer Res. 62:6529–6537. 2002.
|
10.
|
Dor I, Namba M and Sato J: Establishment
and some biological characteristics of human hepatoma cell lines.
Gann. 66:385–392. 1975.PubMed/NCBI
|
11.
|
Terai S, Noma T, Kimura T, Nakazawa A,
Kurokawa F and Okita K: Wild-type p53 gene-induced morphological
changes and growth suppression in hepatoma cells. J Gastroenterol.
32:330–337. 1997. View Article : Google Scholar : PubMed/NCBI
|